LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.
… in patients with LCA10 and preclinical data for ProQR’s Axiomer ® RNA-editing technology. Abstract titles: ○ … through intravitreal injections in the eye. About Axiomer ® Technology Platform ProQR is pioneering a next-generation RNA technology called Axiomer ® , which could potentially yield a new class of …
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
… and key opinion leaders and introduced next-generation Axiomer ® RNA technology platform. LEIDEN, the Netherlands, … trial in 2018. Beyond that, we are excited about the Axiomer ® platform technology we announced at our R&D day. … the event, the Company also introduced its next-generation Axiomer ® RNA technology platform, which has the potential to …
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome